Clarification - Alliance Pharma plc:
This article was originally published in Clinica
Alliance Pharma plc (Chippenham, UK) has asked us to point out that it is not the company that recently received a trial application rejection from a German ethics committee for the intravascular oxygen carrier, Oxyent, as is inferred from the title of the article on page 16 of Clinica No 1231. The company in question is Alliance Pharmaceutical Corp (San Diego, California), as shown in the article's first paragraph.
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.